Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Mr. Stephen P. MacMillan CEO | LSE Exchange | 436440101 CUSIP |
| United States Country | 7,070 Employees | - Last Dividend | 3 Apr 2008 Last Split | 21 Jun 1990 IPO Date |
Hologic, Inc. is a pioneering company focused on improving women’s health through early detection and treatment, leveraging advanced diagnostics, medical imaging systems, and surgical products. Founded in 1985 with its headquarters in Marlborough, Massachusetts, Hologic operates across four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its commitment to innovation and improving patient outcomes positions Hologic as a leader in the healthcare industry, ensuring it meets the diverse needs of healthcare providers and patients alike.